What clinical factors influence your first line treatment selection in advanced HCC?

With now many options of therapy for the treatment of advanced HCC, this is good news. It is also a challenge of how to pick and choose, and what factors may influence the choice of first line treatment.

The possible choices would be either the combination of checkpoint inhibitor plus an add-on thera...

Updated answer - May 5, 2024

The NCCN includes atezolizumab plus bevacizumab and tremelimumab-actl plus durvalumab as category 1 preferred first-line systemic therapy options for HCC.

Updated results from IMbrave150 revealed a median OS and PFS of 19.2 months and 6.9 months respectively, for patient...

Several factors can influence the selection between different treatment options for advanced hepatocellular carcinoma (HCC), including atezolizumab plus bevacizumab (atezo/bev), durvalumab plus tremelimumab (durva/treme), and tyrosine kinase inhibitors (TKIs) like sorafenib or lenvatinib. Factors su...

The main determinant of treating liver cancer patients is still the underlying liver function. For those patients with intact liver function, all treatment options remain available. For those with decompensated liver function, options for active anticancer therapy are limited or in many cases not pu...